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Abstract
Background: Von Hippel-Lindau disease (VHL) is a dominantly inherited familial cancer syndrome predisposing the
patient to a variety of malignant and benign neoplasms, most frequently hemangioblastoma, renal cell carcinoma,
pheochromocytoma, and pancreatic tumors. VHL is caused by mutations of the VHL tumor suppressor gene on the
short arm of chromosome 3, and clinical manifestations develop if both alleles are inactivated according to the
two-hit hypothesis. VHL mutations are more frequent in the coding region and occur occasionally in the splicing
region of the gene. Previously, we reported that the loss of heterozygosity (LOH) of the VHL gene is common in
squamous cell carcinoma tissues of the tongue.
Case Presentation: We describe a case of squamous cell carcinoma in the tongue caused by a point mutation in
the splicing region of the VHL gene and discuss its association with VHL disease. Sequence analysis of DNA
extracted from the tumor and peripheral blood of the patient with squamous cell carcinoma revealed a
heterozygous germline mutation (c. 340 + 5 G > C) in the splice donor sequence in intron 1 of the VHL gene. RT-
PCR analysis of the exon1/intron1 junction in RNA from tumor tissue detected an unspliced transcript. Analysis of
LOH using a marker with a heterozygous mutation of nucleotides (G or C) revealed a deletion of the mutant C
allele in the carcinoma tissues.
Conclusions: The fifth nucleotide G of the splice donor site of the VHL gene is important for the efficiency of
splicing at that site. The development of tongue cancer in this patient was not associated with VHL disease
because the mutation occurred in only a single allele of the VHL gene and that allele was deleted in tumor cells.
Background
Von Hippel-Lindau (VHL) disease has a prevalence of
about 1 per 36,000 people with 20% of cases being spora-
dic and 80% familial [1,2]. The causal gene, VHL,i s
located on chromosome 3p26-25 and is known to act as
a tumor-suppressor gene [3]. It has three exons that code
for 213 amino acids and has functions to promote ubi-
quitination of hypoxia inducible factor 1- alpha [4].
There are characteristic abnormalities of the VHL gene
in germline mutations from VHL disease and somatic
mutations from sporadic cancers: more than a half of the
former are missense mutations whereas 70% of the latter
are frameshift mutations [5,6]. Thus, most pathogenic
mutations are located in the coding region of the VHL
gene. There are a few cases with splicing abnormality of
the VHL gene and it is not yet clear whether an abnormal
transcript of the VHL is pathogenic. In this report, we
describe a splicing abnormality of the VHL gene in a
patient with a squamous cell carcinoma (SCC) of the
tongue.
Case Presentation
The patient is a 55-year male with a tumor of the tongue,
whose biopsy revealed a SCC. The cancerous tissue of the
tongue along with peripheral blood were collected and
stored at -80°C. Control material, both cancerous and non-
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did not have a VHL mutation. DNA was extracted from
the tissue lysate using the phenol/chloroform method.
DNA was extracted from whole blood as described pre-
viously [7]. Total RNA was prepared from cancerous tissue
using Trizol (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. The study was approved by
the Ethical Committee of Nihon University School of Med-
icine, conforming to the Helsinki Declaration. The patient
gave his written informed consent to participate in this
study and for publication of this case report.
The three exons of the VHL gene, and their flanking
regions, were amplified as described previously [6]. The
polymerase chain reaction (PCR) product was purified
with a Microcon 100 filter (Amicon, Inc., Beverly, Mass.)
and sequenced using a BigDye Terminator Cycle Sequen-
cing kit (Applied Biosystems, Foster City, CA). We deter-
mined nucleotide sequences using an ABI310 Genetic
Analyzer. We observed a heterozygous c. 340 + 5 G > C
point mutation of the VHL gene in the DNA from the
cancerous tissue and peripheral blood of the patient with
SCC of the tongue, but not in the control (Figure 1).
Figure 1 Sequence profiles of exon 1 to intron 1 of the VHL gene. The sequence of exon 1 to intron 1 of the VHL gene is shown in
double- stranded form at the top. We compared DNA sequence from the cancerous tissue (A) and the peripheral blood (B) of the SCC patient
to the non-cancerous tissue of a control patient (C). We observed a heterozygous c. 340 + 5 G > C point mutation of the VHL gene in the DNA
from the cancerous tissue (A) and peripheral blood (B) of the patient with SCC of the tongue, but not in the control (C). The DNA from the
peripheral blood of the patient was also sequenced in the reverse direction (D).
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therefore lead to an unspliced transcription product.
To determine whether this had occurred, we amplified
the transcription product using RT-PCR and performed
real time PCR. Briefly, cDNA was synthesized from 2 μg
of DNase I-treated RNA from tumor tissue using 50
pmol of random primers and 5 units of AMV reverse
transcriptase version 2.2 (Life Sciences, St. Petersburg,
Florida, USA). To identify the exon 1-intron 1 and exon
1-exon 2 regions, we performed SYBR Green PCR
(Applied Biosystems) according to the manufacturer’s
instructions using intron primers E1/I1F (5’-CACAGCT
ACCGAGGTACCG-3’)a n dI 1 R( 5 ’-GAATGCTCT-
GACGCTTACGA-3’), and exon primers 1/2 F (5’-AGC-
TACCGAGGTCACCTTTG-3’) and 2/3R (5’-CAGAGT
ATACACTGGCAGTG-3’), respectively. The amplifica-
tions were carried out by 40 cycles at 95°C for 15 sec
and 60°C for 60 sec using an ABI7000 (Applied Biosys-
tems). As a control, we used glyceraldehyde 3-phosphate
dehydrogenase (GAPDH)g e n ep r i m e r s( 5 ’-GGTCGG
AGTCAACGGATTTG-3’ and 5’-GCATCTCG CTCC
TGGAAGAT-3’). PCR products were run on 2% agarose
gels to confirm fragment sizes.
As shown in Figure 2C, in our patient, a product of
167 bp was obtained by RT-PCR of tumor RNA with
the exon 1/intron1 primer pair (E1/I1F and I1R), indi-
cating that splicing of intron 1 had not occurred, at
least in a portion of VHL transcripts. We confirmed that
the transcript contained the intron sequence by direct
sequencing (data not shown). Analysis of cDNA from
the control patient did not produce a similar length
transcription product. We ens u r e dt h a tt h er e s u l tf r o m
our intron RT-PCR was not a signal from contaminating
DNA by treating the total RNA samples with DNase I
prior to cDNA production (Figure 2). Semi-quantitative
analysis suggested that the relative amount of transcripts
in tumor tissue exhibiting abnormal splicing of intron 1
was only 1.5% of that exhibiting normal splicing of exon
2 and 3.
Then, loss of heterozygosity (LOH) of the VHL gene was
determined by SNaPshot quantification as described pre-
viously [8]. Briefly, PCR was performed using two pairs of
primers at the heterozygous point mutation G/C of the
intron 1 splice donor site: E1/I1F (5’-CACAGCTACCG
AGGTACCG-3’)a n dI 1 R( 5 ’-GAATGCTCTGACGCT-
TACGA-3’) and at the SNP A/G of the exon 3: AGF (5’-
CTGCCCATTAGAGAAGTATTT-3’) and AGR (5’-AAT
TCCCACTGAATTACGTATA-3’). After purification
using a Microcon 100 filter, the amplified product was
subjected to a primer extension reaction using SNaPshot
Figure 2 RT-PCR of VHL transcripts. A. Primer positions of intron and exon PCR. B. Amplification plots of real-time PCR. We performed real-
time PCR for cDNA from the cancerous tongue tissue from the patient and cDNA from non-cancerous tissue of the control. GAPDH mRNA was
quantified as an internal control. C. Agarose gel electrophoresis of real-time PCR products. The PCR product obtained from (B) was run on a 2%
agarose gel for electrophoresis. Lane I, intron PCR (167 bp); lane E, exon PCR (144 bp); lane G, GAPDH PCR; lane G (-), GAPDH PCR using DNase-
treated RNA without reverse transcription as a template; lane M, HincII digests of x174 phage DNA.
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5’-GCCGCATCCACAGCTACCGAGGTAC-3’ and 5’-
AGTCAGGACAGCTTGTATGTAAGGAGGTTT-3’,
respectively. The primer extension product was quantified
using an ABI 310 genetic analyzer and GeneScan software
(Applied Biosystems). The LOH analysis at the heterozy-
gous point mutation (c.340 G > C) in intron 1 revealed
that the tumor tissue had levels of the mutant allele that
were about 50% lower than that observed in peripheral
blood, suggesting loss of the mutant allele in tumor tissue
(Figure 3). Thus, the reduction in intron transcription pro-
duct was due to the loss of the mutant allele in the cancer-
ous tissue.
As shown on Figure 1, we have found a germline point
mutation, c.340 + 5 G > C, in the intron 1 splice donor
site of the VHL gene of a patient with SCC of the tongue.
We demonstrated that this base substitution was a muta-
tion that produces a transcription product with abnormal
splicing. This is the first report of abnormal splicing due
to a mutation at the +5 position in intron 1 of the VHL
gene. If the novel transcription product is translated with-
out being spliced, then 35 amino acids and a stop codon
would be read from intron 1. The C-terminally truncated
polypeptide would compromise the elongin binding.
The consensus sequence of exon-intron junctions is
5’-A64G73 /G100T100A62A68G84T63-3’ in which the sub-
scripts indicate the percent occurrence of the specified
base. U1 snRNA (3’-UCCAUUCAUApppGm-5’)b a s e
pairs directly with the 5’ splice site at the first stage of
splicing. The extent of complementarity between U1
snRNA and the 5’ splice site is 4-6 bp. The exon 1-
intron 1 junction of the VHL gene is 5’-AG/GTACGG-
3’ in which the +4 and +6 positions of intron 1 are
unpaired with U1 snRNA. Therefore, +5 position must
be important to start splicing by base pairing with U1
snRNA.
Figure 3 LOH of the VHL gene. LOH was analyzed at the heterozygous point mutation G/C of the intron 1 splice donor site and at the SNP A/
G of the exon 3 of the VHL gene using a quantitative genotyping method. Comparison of cancerous tissue (T) and the peripheral blood (B) of
the SCC patient indicated that the cancerous tissue had lost the mutant C allele (arrow) and the SNP A allele (arrow).
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gene has been found in numerous patients with VHL dis-
ease. Point mutations at IVS1 + 1 [9,10] or IVS1-1 [10],
and an insertion or deletion at the IVS1 splice site [10,11]
were found in several cases of VHL disease. The point
mutation found here at IVS1 + 5 (G to C conversion) was
present in cases of VHL disease type 1 [11-14]. Therefore,
a point mutation at IVS1 + 5 can result in the abnormal
splicing and are pathogenic. However, although there is
abnormal splicing in the present case, the patient did not
fulfill the current clinical diagnostic criteria of VHL dis-
ease [15] and had no family history of VHL disease. There
are two possible interpretations for this apparent paradox.
First, the patient has not yet developed VHL disease. Sec-
ond, the mutation may not always be pathogenic and the
patient will not develop VHL disease. Erlic et al. ques-
tioned the pathogenicity of the c.340 + 5 G > C mutation
since it did not segregate with VHL in his family [16]. The
question arises of whether the tongue cancer of the pre-
sent patient is a VHL disease-associated cancer? The
answer appears to be that it is not as there was no second
hit from somatic cell mutation of the wild type VHL allele,
although there was loss of the mutant allele in the tumor
tissue. It is possible that the single hit allelic loss of the
VHL gene increased the risk of cancer development.
Recently, we observed frequent LOH of the VHL gene in
sporadic tongue cancer but no somatic cell mutations
such as missense, nonsense, and frameshift mutations
[17]. LOH of several microsatellites on 3p was also
detected in significant proportion of tongue cancer
patients, and such deletions were often observed simulta-
neously across a large region of 3p within the same tumor
sample [17]. The present patient showed LOH at all 5
informative microsatellites examined on 3p in addition to
the VHL gene [17]. Thus, multiple tumor-suppressor
genes on 3p may play a role in the development of tongue
cancer in the present case.
Conclusions
The fifth nucleotide G of the splice donor site of the VHL
gene is important for the efficiency of splicing at that site.
The development of tongue cancer in this patient was
not associated with VHL disease because the mutation
occurred in only a single allele of the VHL gene.
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